№ files_lp_3_process_7_071688
File format: docx
Character count: 48075
File size: 414 KB
Supplementary Appendix for a randomized clinical trial on the effect of subcutaneous REGEN-COV antibody combination in treating early asymptomatic SARS-CoV-2 infection.
Year:
2021
Region / city:
Various locations in the United States
Topic:
COVID-19 Treatment
Document type:
Clinical Trial Report
Institution:
Regeneron Pharmaceuticals, NIAID/CoVPN
Author:
Multiple investigators and research teams
Target audience:
Healthcare professionals, researchers, clinical trial coordinators
Period of validity:
Study conducted during 2020-2021
Approval date:
Not specified
Date of changes:
Not specified
Price: 8 / 10 USD
The file will be delivered to the email address provided at checkout within 12 hours.
The file will be delivered to the email address provided at checkout within 12 hours.
Don’t have cryptocurrency yet?
You can still complete your purchase in a few minutes:- Buy Crypto in a trusted app (Coinbase, Kraken, Cash App or any similar service).
- In the app, tap Send.
- Select network, paste our wallet address.
- Send the exact amount shown above.
The final amount may vary slightly depending on the payment method.
The file will be sent to the email address provided at checkout within 24 hours.
The product description is provided for reference. Actual content and formatting may differ slightly.
Year:
2011
Region / city:
Italy, Norway
Subject:
Cardiovascular diseases, Aortic stenosis
Document type:
Original article
Author:
Giovanni Cioffi, Pompilio Faggiano, Enrico Vizzardi, Luigi Tarantini, Dana Cramariuc, Eva Gerdts, Giovanni de Simone
Target audience:
Healthcare professionals, researchers in cardiology
Period of validity:
N/A
Date of approval:
15 June 2010
Date of changes:
N/A
Year:
2022
Region / City:
Birmingham, Wolverhampton
Topic:
Cardiovascular Health, Aortic Stenosis, Remote Monitoring
Document Type:
Research Study Participant Information Sheet
Organization:
University of Birmingham, The Royal Wolverhampton NHS Trust
Author:
Cardiovascular Research Team
Target Audience:
Patients with asymptomatic severe aortic stenosis
Period of Effect:
12 months
Approval Date:
11.12.2022
Date of Changes:
N/A
Year:
2023
Region / City:
White Mountain
Topic:
Asymptomatic Bacteriuria, Antibiotic Stewardship
Document Type:
Final Report
Organization / Institution:
White Mountain IQIC
Author:
Unknown
Target Audience:
Healthcare Providers, Medical Researchers
Period of Action:
June 2023
Approval Date:
June 2023
Date of Changes:
None
Note:
Date
Agency / Institution:
Centers for Disease Control and Prevention (CDC)
Year:
2023
Region / City:
Australia
Subject:
Chronic migraine, medicinal product submission
Document type:
Submission for PBS listing
Organization:
Novartis Pharmaceuticals Australia Pty. Limited
Author:
Not specified
Target audience:
Health professionals, pharmaceutical regulatory bodies
Period of validity:
Not specified
Date of approval:
2 July 2018
Date of amendments:
November 2023
Note:
Year
Theme:
Rheumatology, Methotrexate Therapy, Drug Interaction
Document Type:
Medical Guidelines
Target Audience:
Healthcare Professionals, Specialists
Year:
2021
Region / city:
Canberra
Topic:
Subcutaneous Medication Administration in Palliative Care
Document Type:
Procedure
Organization / institution:
Canberra Health Services
Author:
Canberra Health Services
Target audience:
Healthcare professionals, specifically nursing staff in palliative care settings
Period of validity:
Ongoing
Approval Date:
2021
Amendment Date:
Not specified
Year:
2022
Region / City:
ACT and surrounding NSW
Topic:
Paediatric Diabetes Care, Insulin Pump Therapy
Document Type:
Clinical Guideline
Organization:
Canberra Health Services (CHS)
Author:
Canberra Health Services, Paediatric Endocrinology and Diabetes Service
Target Audience:
Paediatric Diabetes Healthcare Providers
Period of Validity:
N/A
Approval Date:
N/A
Date of Last Revision:
N/A
Year:
2026
Region / City:
Australia
Theme:
Medical Travel, Blood Products, SCIg
Document Type:
Official Guidelines
Organization / Institution:
Australian Red Cross Lifeblood, National Blood Authority, Victorian Government Department of Health
Author:
Victorian Government, Department of Health
Target Audience:
Medical professionals, Patients requiring SCIg
Period of Validity:
Not specified
Date of Approval:
January 2026
Date of Last Update:
January 2026
Version:
HNY v3.0
Replaces version:
HNY v2.0
Clinical content last reviewed:
November 2023
Next review date:
July 2028
Local approval:
1st October 2025
Target population:
Adults aged 18 and over, excluding cancer care
Indications:
Licensed and off-label use in rheumatoid arthritis, Crohn’s disease, psoriasis, psoriatic arthritis, and other chronic inflammatory conditions
Administration routes:
Oral, subcutaneous
Monitoring requirements:
Blood tests, infection screening, vaccination advice, renal function assessment, pregnancy considerations
Responsible organizations:
HNY ICB, RDTC
Document type:
Shared Care Protocol
Contextual description:
Clinical guidance source detailing licensed and off-label methotrexate indications, administration, monitoring, and transfer protocols between specialist and primary care for adults in non-cancer services.
Note:
Version Number 2.3
Year:
2025
Region / City:
United Kingdom
Theme:
Sexual and Reproductive Health
Document Type:
Patient Group Direction (PGD)
Organisation:
Faculty of Sexual and Reproductive Health (FSRH)
Author:
Dr. Cindy Farmer, Michelle Jenkins, Elaine Scott, Kalpesh Thakrar, Sim Sesane, Tanya Lane, Kate Devonport, Chetna Parmar, Carmel Lloyd, Clare Livingstone, Portia Jackson, Kirsty Armstrong, Dipti Patel, Emma Anderson, Alison Crompton, Lisa Knight, Bola Sotubo, Tracy Rogers, Sandra Wolper, Jo Jenkins, Rosie Furner
Target Audience:
Registered healthcare professionals authorised to practice under this PGD
Period of Effect:
May 2023 - April 2026
Approval Date:
December 2022
Review Date:
October 2025
Expiry Date:
April 2026
Year:
2023
Region / city:
Australia
Topic:
Rheumatology, Pharmaceutical Listings
Document type:
Submission to Pharmaceutical Benefits Advisory Committee (PBAC)
Organization:
Link Medical Products Pty Ltd
Author:
Not specified
Target audience:
Healthcare professionals, PBAC members
Period of validity:
Not specified
Approval date:
Not specified
Date of changes:
Not specified
Note:
Context
Organisation:
Hope Vets
Address:
Shantock Hall Lane, Bovingdon, HP3 0NQ
Telephone:
01442 833198
Email:
[email protected]
Website:
www.hopevets.com
Document type:
Instructional handout
Subject:
Administration of subcutaneous injections in pets
Medications mentioned:
Cytopoint, Librela, Solensia, Zycortal, insulin
Intended audience:
Pet owners administering injections at home
Related resources:
YouTube videos; Caninsulin website
Sharps disposal guidance:
Return to veterinary practice; use of sharps container or sealed container
Year:
2021
Region / City:
Winston-Salem, NC
Topic:
Vitamin K, INR reversal, Subcutaneous administration, Community healthcare
Document Type:
Case series
Author:
Gretchen Ingling, Laura Coles
Target Audience:
Healthcare professionals, Pharmacists, Physicians
Period of Action:
July 1, 2020 – July 1, 2021
Date of Approval:
Not specified
Date of Modifications:
Not specified
Time limit:
3 minutes
Total points:
50
Subject:
Subcutaneous injection procedure
Type of document:
Skills assessment rubric
Field:
Veterinary medicine
Assessment format:
Practical examination
Evaluation method:
Point-based scoring system
Target participants:
Students
Performance requirement:
Verbal explanation of steps during practicum
Maximum points per section:
10
Additional evaluation criteria:
Communicative ability, professionalism, articulation, customer relations
Year:
2026
Region / City:
United Kingdom
Subject:
Reproductive health; contraceptive administration
Document type:
Patient Group Direction (PGD)
Authorising body:
College of Sexual and Reproductive Healthcare (CoSRH)
PGD development group:
Reproductive Health PGDs Short Life Working Group (SLWG)
Approving organisations:
NHS Trusts and local health authorities
Target audience:
Registered healthcare professionals authorised to use the PGD
Effective date:
1 May 2026
Review date:
1 November 2028
Expiry date:
30 April 2029
Version:
3.0
Change history:
Includes updates on contraindications, cautions, and terminology alignment with UKMEC 2025 and CoSRH guidance
Training requirements:
Authorised HCPs must complete specified education and competency assessment
Legal compliance:
Must be signed by senior doctor, senior pharmacist, and organisational representative
Description:
Official national PGD detailing the conditions, contraindications, administration procedure, and authorisation requirements for SC-DMPA use by qualified healthcare professionals, including a comprehensive version history and governance framework.
Year:
2023
Region / City:
N/A
Topic:
Veterinary Care
Document Type:
Instructional Guide
Organization / Institution:
N/A
Author:
N/A
Target Audience:
Pet Owners
Effective Period:
N/A
Approval Date:
N/A
Modification Date:
N/A
Year:
2023
Region / City:
Hatfield, UK
Subject:
Veterinary Medicine
Document Type:
Case Report
Institution:
Royal Veterinary College
Author:
Charalampos Attipa, Rachel Hampel, Simon L. Priestnall, Kate English
Target Audience:
Veterinarians, Veterinary Students
Date of Approval:
2023
Date of Changes:
N/A
Year:
2022
Journal:
World Journal of Clinical Cases
Manuscript Type:
Case Report
Authors:
Miao Zhang, Jia Chen, Chun-Xiao Wang, Nai-Xuan Lin, Xin Li
Affiliations:
Department of Dermatology, Yueyang Hospital of Integrated Traditional Chinese and Western Medicine, Shanghai University of Traditional Chinese Medicine; Institute of Dermatology, Shanghai Academy of Traditional Chinese Medicine; Department of Dermatopathology, Shanghai Skin Disease Hospital, Tongji University
Corresponding Author:
Xin Li, MD, PhD
Received Date:
May 31, 2022
Revised Date:
July 9, 2022
Accepted Date:
August 23, 2022
Published Online:
2022
Keywords:
Vitamin K1, Subcutaneous injection, Adverse reactions, Herbal medicine, Polyoxyethylated castor oil, Case report guidelines
Target Audience:
Clinicians, Dermatologists, Researchers in clinical medicine
Patient Age:
50 years
Patient Condition:
Cutaneous allergic reaction to vitamin K1
Treatment:
Chinese herbal medicine, topical and intralesional steroids
Follow-up Duration:
32 months